Retatrutide — the investigational triple agonist targeting GLP-1, GIP, and glucagon receptors — has generated significant clinical interest since its Phase 2 results were published in the New England Journal of Medicine in 2023. The more recent TRIUMPH-4 Phase 3 trial, results of which were announced by Eli Lilly in December 2025, reported a mean weight loss of 28.7% at the 12mg dose over 68 weeks — the highest figure ever recorded in a Phase 3 obesity trial. Commonly referred to as reta in patient communities, this molecule is drawing attention not only for its efficacy but for a tolerability profile that deserves careful clinical discussion. With a peer-reviewed Phase 3 publication and an NDA filing both still pending as of April 2026, it is important that patients and their physicians understand the safety signals emerging from available data before making any future treatment decisions.
Discontinuation rates are one of the most practical measures of a drug's real-world tolerability — they reflect not just adverse events, but patients' willingness to continue treatment despite them. In TRIUMPH-4, discontinuation rates were 12.2% at the 9mg dose and 18.2% at the 12mg dose, compared to just 4.0% in the placebo group over 68 weeks of treatment.
The Phase 2 trial, which ran for 48 weeks with doses up to 12mg weekly, did not report discontinuation in the same granular format, but the most commonly cited adverse events — nausea, diarrhea, and vomiting — were described as dose-dependent and predominantly clustered during the titration phase. These GI effects are consistent with the mechanism of GLP-1 receptor agonism and are well-recognized across this drug class.
The Phase 3 titration schedule in TRIUMPH-4 was notably gradual: participants started at 2mg for weeks 1–4, escalated to 4mg (weeks 5–8), then 6mg (weeks 9–12), 9mg (weeks 13–16), before reaching the 12mg maintenance dose at week 17 onward. Despite this careful stepwise escalation, discontinuation at the 12mg maintenance dose still exceeded 18%. This suggests that for a meaningful subset of patients, tolerability challenges extend beyond the titration window — a clinically important distinction from prior assumptions that most GI burden resolves once a stable dose is reached.
Dysesthesia refers to abnormal, often unpleasant sensations — burning, tingling, prickling, or hypersensitivity to touch — that occur without an obvious external stimulus. In TRIUMPH-4, dysesthesia was reported in 8.8% of participants at the 9mg dose and 20.9% at the 12mg dose, compared to just 0.7% in the placebo group.
This signal was already visible in Phase 2 data. Using MedDRA terminology that grouped hyperesthesia and dysesthesia together, the Phase 2 supplementary tables reported rates of 12.9% at 12mg and 14.3% at 8mg (initial dose 4mg), versus 1.4% in placebo. The Phase 3 TRIUMPH-4 figures at 12mg — 20.9% — are meaningfully higher than Phase 2 estimates, which may reflect the longer treatment duration (68 weeks vs. 48 weeks), the larger sample size providing greater statistical power, or both.
The biological mechanism underlying dysesthesia with retatrutide is not yet fully characterized in the published literature. The glucagon receptor component — which distinguishes retatrutide from dual agonists like tirzepatide — may play a role given glucagon's known activity in peripheral and central nervous system signaling, but this remains an area of active investigation. Clinically, most dysesthesia events in Phase 2 were not described as treatment-limiting for the majority of affected participants, though the TRIUMPH-4 discontinuation data suggest that at the 12mg dose, some patients found the cumulative adverse event burden difficult to sustain.
One of the most striking and genuinely novel findings from TRIUMPH-4 was that some participants discontinued treatment due to perceived excessive weight loss. This is, to put it plainly, a finding with almost no precedent in obesity pharmacotherapy. The concept of patients discontinuing a weight-loss medication because they felt they had lost too much weight would have seemed implausible in clinical discussions just a decade ago.
This finding speaks to the extraordinary potency of retatrutide — sometimes called the triple G in patient communities for its three-receptor mechanism — at the 12mg dose. A mean weight loss of 28.7% over 68 weeks means that many participants lost substantially more than the average. For individuals with a starting BMI of 35–40, that can translate to 60–80 or more pounds of total body weight, and for some, the pace or magnitude of loss prompted concern about their physical appearance, muscle mass, or overall sense of wellbeing.
This finding carries an important clinical implication: dose selection should not default automatically to the highest available dose. The 9mg dose, which still produced clinically substantial weight loss with a somewhat lower discontinuation rate (12.2%) and lower dysesthesia burden (8.8%), may represent a more appropriate target for patients who prioritize tolerability or who express concern about the pace of weight reduction.
The data available from both Phase 2 and TRIUMPH-4 support a benefit-risk framework in which the 12mg dose offers maximum efficacy but a meaningfully higher tolerability burden. The table below summarizes the key tolerability and efficacy comparisons across doses and trials.
| Parameter | Placebo | Retatrutide 9mg (TRIUMPH-4) | Retatrutide 12mg (TRIUMPH-4 / Ph2) |
|---|---|---|---|
| Mean weight loss | ~2.1% (Ph2, 48 wk) | Not separately disclosed | 28.7% (TRIUMPH-4, 68 wk); 24.2% (Ph2, 48 wk) |
| Discontinuation rate | 4.0% | 12.2% | 18.2% |
| Dysesthesia rate | 0.7% | 8.8% | 20.9% (TRIUMPH-4); 12.9% (Ph2) |
| ≥25% weight loss at 48 wk (Ph2) | 0% | N/A | 48% (12mg, initial dose 2mg) |
| GI adverse events | Low | Dose-dependent; peaked during titration | Dose-dependent; peaked during titration |
Several principles emerge from this data for patients considering retatrutide once it becomes available:
It is also worth acknowledging what remains unknown. The peer-reviewed Phase 3 publication has not yet appeared as of April 2026, and an NDA has not yet been filed. Full characterization of the dysesthesia events — their onset timing, severity grading, reversibility, and management strategies — awaits complete Phase 3 reporting. Longer-term safety data beyond 68 weeks are not yet available. The reduction of "food noise" — the persistent intrusive thoughts about eating that many patients with obesity describe — has been reported anecdotally in patient communities using GLP-1 class agents, but formal Phase 3 characterization of this patient-reported outcome for retatrutide is pending.
Retatrutide represents a genuinely significant advance in obesity pharmacotherapy, with efficacy data that exceeds anything previously seen in a Phase 3 trial. The tolerability data from TRIUMPH-4, however, reinforce that no medication with this level of biological potency comes without a clinically meaningful adverse event profile. The decision of whether to pursue the 12mg target dose — or to remain at 9mg — will ultimately depend on individual patient goals, baseline health status, and response to titration, and should involve a thorough, individualized clinical conversation.
If retatrutide is a medication worth following closely, the glp3md.com waitlist exists to keep interested patients informed as the regulatory and clinical landscape develops. Joining the waitlist at https://www.glp3md.com provides access to updates on TRIUMPH-4 publications, NDA filing timelines, and emerging clinical guidance — please note that joining the waitlist does not constitute a promise or guarantee of treatment, prescriptions, or medication availability, as retatrutide remains an investigational agent that has not received FDA approval.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.